A subset of bone marrow cells known as proangiogenic cells (PACs) may drive the development of pulmonary arterial hypertension…
Articles by José Lopes, PhD
Arena Pharmaceuticals and United Therapeutics have reached a global licensing agreement for the pulmonary arterial hypertension (PAH) therapy candidate ralinepag.
Patients with pulmonary hypertension (PH) and severe aortic stenosis (AS), who have a specific, less frequent blood flow pattern, have worse cardiac…
Extended-release tablets of ralinepag, Arena Pharmaceuticals’ treatment candidate for pulmonary arterial hypertension (PAH), show a superior pharmacokinetic profile…
Inhibition of proteins that regulate gene expression — called BET — were found to ease pulmonary hypertension (PH) in a rat…
Research & DevelopmentTreatment with the approved anti-cancer medication sorafenib reversed pulmonary arterial hypertension (PAH) and cardiopulmonary remodeling (CPR)…
Estimated survival in patients with either pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) is worse…
SOX17 may be a risk gene that contributes to pulmonary arterial hypertension (PAH) associated with congenital heart…
An enzyme called NOX4 appears to have a crucial role in the blood vessel remodeling that can lead to pulmonary hypertension…
Infusions of large doses of intravenous iron may be a safe treatment approach for patients with low oxygen levels in their…
A cancer marker called NEDD9 is a critical mediator of pulmonary arterial hypertension (PAH) and could be a therapeutic…
Chronic thromboembolic pulmonary hypertension (CTEPH) may be an inherited genetic disease, a new study suggests. The results were recently presented at…